cbdMD, Inc. (YCBD) |
| 0.779 0.051 (7.01%) 04-15 15:59 |
| Open: | 0.711 |
| High: | 0.779 |
| Low: | 0.711 |
| Volume: | 375,873 |
| Market Cap: | 8(M) |
| PE Ratio: | 1.3 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.96 |
| Resistance 1: | 0.82 |
| Pivot price: | 0.72 |
| Support 1: | 0.70 |
| Support 2: | 0.63 |
| 52w High: | 2.56 |
| 52w Low: | 0.47 |
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Wed, 15 Apr 2026
cbdMD (NYSE: YCBD) grants RSUs and raises cash retainers for directors - Stock Titan
Wed, 01 Apr 2026
cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare - Nasdaq
Sat, 21 Mar 2026
If You Invested $1,000 in Cbdmd Inc (YCBD) - Stock Titan
Tue, 17 Feb 2026
cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026 - Yahoo Finance
Wed, 14 Jan 2026
cbdMD Announces Strategic Acquisition of Bluebird Botanicals - PR Newswire
Fri, 19 Dec 2025
cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |